文献速递神经肿瘤

75岁及以上极老年胶质母细胞瘤患者的治疗:哪些患者应接受治疗

Treatment of very elderly glioblastoma patients ≥ 75 years of age: whom to treat.
PubMed 文献 · J Neurooncol · 2023-11-30

本回顾性研究纳入2010至2018年在本机构治疗的143例≥75岁胶质母细胞瘤患者,中位年龄79岁,104例仅活检、39例切除,全队列中位总生存5.9个月;多因素分析证实辅助放疗和化疗是影响总生存的独立因素,未证实切除的获益。

要点

  • ≥75岁胶质母细胞瘤患者全队列中位总生存5.9个月。
  • 多因素分析显示辅助放疗和化疗是总生存的独立影响因素。
  • 未证实手术切除较活检带来生存获益。

核心结论

  • 极老年患者未经治疗的自然病程极差,可从包括辅助放疗和化疗在内的多模式治疗中获益,切除的获益尚未得到证实,治疗决策前应充分讨论治疗方案与结局。

研究设计与样本

  • 回顾性研究,2010年至2018年在本机构共治疗977例胶质母细胞瘤患者,其中143例诊断时年龄≥75岁;主要手术方式为切除或活检,随后尽可能行辅助治疗。

主要发现

  • 极老年患者中位年龄79岁(范围75-110岁),104例仅行活检,39例行切除,全队列中位总生存5.9个月。
  • 单因素分析显示,就诊时KPS≥70 vs ≤60(6 vs 3个月,p<0.0111)、手术切除 vs 活检(12 vs 4个月,p=0.0011)、辅助化疗 vs 无(11 vs 4个月,p=0.0003)、辅助放疗 vs 无(10 vs 1.5个月,p<0.0001)均与总生存显著相关。
  • 多因素分析证实辅助放疗(p<0.0001)和化疗(p=0.0002)是影响总生存的独立因素。

临床怎么用

  • 作者认为极老年患者可从包括辅助放疗和化疗在内的多模式治疗中获益,切除的获益尚未得到证实,治疗决策前应充分讨论治疗方案与结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The prognosis of patients ≥ 75 years suffering from glioblastoma is poor. Novel therapies are usually reserved for patients ≤ 70 years. In an aging population, treatment of very elderly patients remains a challenge. METHODS: Between 2010 and 2018, a total of 977 glioblastoma patients were treated at our institution. Of these, 143 patients were ≥ 75 years at diagnosis. Primary procedure was surgical resection or biopsy followed by adjuvant treatment, whenever possible. We retrospectively investigated overall survival (OS) and potential prognostic factors influencing survival, including Karnofsky Performance Status (KPS), surgical therapy, adjuvant therapy as well as MGMT promotor status. RESULTS: In very elderly patients, median age was 79 years (range: 75-110). Biopsy only was performed in 104 patients; resection was performed in 39 patients. Median OS for the entire cohort was 5.9 months. Univariate analysis showed that KPS at presentation (≥ 70 vs. ≤60), surgery vs. biopsy, adjuvant chemotherapy and adjuvant radiotherapy were significantly associated with OS (6 vs. 3, p < 0.0111; 12 vs. 4, p = 0.0011; 11 vs. 4, p = 0.0003 and 10 vs. 1.5 months, p < 0.0001, respectively). Multivariate analysis confirmed adjuvant radiotherapy (p < 0.0001) and chemotherapy (p = 0.0002) as independent factors influencing OS. CONCLUSION: For very elderly patients, the natural course of disease without treatment is devastating. These patients benefit from multimodal treatment including adjuvant radiotherapy and chemotherapy. A beneficial effect of resection has not been demonstrated. Treatment options and outcomes should be thoughtfully discussed before treatment decisions are made.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Baumgarten P, Prange G, Kamp MA, et al. Treatment of very elderly glioblastoma patients ≥ 75 years of age: whom to treat. J Neurooncol. 2023. PMID: 38032426. doi:10.1007/s11060-023-04518-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。